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Background: Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors with diverse subtypes. STS can be
classified into two main categories according to the type of genomic alteration: recurrent translocation driven STS,
and non-recurrent translocations. However, little has known about acquired uniparental disomy in STS.
Methods: In this study, we analyzed SNP microarray data to determine the frequency and distribution patterns of
acquired uniparental disomy (aUPD) in major soft tissue sarcoma (STS) subtypes using CNAG and R softwares.
Results: We identified recurrent aUPD regions specific to alveolar rhabdomyosarcoma with the most frequent at
11p15.4, gastrointestinal stromal tumor at 1p36.11-p35.3, leiomyosarcoma at 17p13.3-p13.1, myxofibrosarcoma at
1p35.1-p34.2 and 16q23.3-q24.1, and pleomorphic liposarcoma at 13q13.2-q13.3 and 13q14.11-q14.2. In contrast,
specific recurrent aUPD regions were not identified in dedifferentiated liposarcoma, Ewing sarcoma, myxoid/round
cell liposarcoma, and synovial sarcoma. Strikingly total, centromeric and segmental aUPD regions are more frequent
in STS that do not exhibit recurrent translocation events.
Conclusions: Our study yields a detailed map of aUPD across 9 diverse STS subtypes and suggests the potential
location of several novel tumor suppressor genes and oncogenes.
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Soft tissue sarcoma (STS) is a heterogeneous disease with
50 clinically relevant subtypes with different histology,
molecular genetic profiles, tumor locations, and prognosis
[1-3]. Genomic alterations including specific DNA copy
number alterations, [4] chromosomal translocations, and
mutations are hallmarks of different subtypes of STS. STS
can be classified into two main categories according to the
type of genomic alteration: i) recurrent translocation
driven STS, with reciprocal translocation resulting in
oncogenic fusion transcripts (e.g. EWSR1-FLI1 in Ewing
sarcoma, SS18-SSX in synovial sarcoma, PAX3-FOXO1 in
alveolar rhabdomyosarcoma (aRMS), FUS-CHOP in myx-
oid/round-cell (MRC) liposarcoma), and [5] ii) STS with
non-recurrent translocations (e.g. myxofibrosarcoma,
leiomyosarcoma, liposarcoma [dedifferentiated liposar-
coma and pleomorphic liposarcoma]). The non-recurrent
translocation group tends to show complex genomic* Correspondence: mtuna9@gmail.com
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reproduction in any medium, provided the orchanges including gains/amplifications and deletions in
multiple chromosomal regions, [3,6] or activating
mutations (e.g. KIT and PDGFRA) in gastrointestinal
stromal tumors (GIST). According to the World Health
Organization (WHO) classification, liposarcomas are
further classified into four morphological subtypes: well-
differentiated liposarcoma, de-differentiated liposarcoma,
pleomorphic liposarcoma, and myxoid/round-cell liposar-
coma (MRC), which enables characterization of the indi-
vidual liposarcoma subtypes [7]. MDM2 amplification at
chromosome 12q13-q15, which is present in all tumor
samples, is a key driver of dedifferentiated liposarcoma
[8,9]. Pleomorphic liposarcoma tumor samples harbor
gains and deletions in multiple chromosomal regions with
the most common being deletion (60%) at chromosome
13q14.2-q14.3 (RB1) in addition to complex genomic
rearrangements [10]. Mutations are common in different
types of liposarcoma including TP53 mutations in 17% of
pleomorphic liposarcomas; NF1 mutations in 10.5% of
myxofibrosarcoma, 8% of pleomorphic liposarcomas; and
PIK3CA mutations in 18% of MRC [11].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Frequency of segmental, whole chromosome,
centromeric and telomeric aUPD in all samples.
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allow the detection of copy number alterations and
acquired uniparental disomy (aUPD also known as copy
number neutral loss of heterozygosity), which occurs
when both copies of a chromosome originate from the
same parent, in the most cases without a change in copy
number. There are two major mechanisms leading to
aUPD: mitotic recombination of sister chromatids, which
results to segmental aUPD, or the loss of a complete
chromosome followed by duplication resulting in whole
chromosome aUPD.
aUPD regions may cause pre-existing abnormalities
(mutation, deletion, amplification, methylation, histone
modification, and/or imprinting) to become homozygous,
which may lead to clonal selection and growth advantage
in the cells. To date, aUPD has been described mostly in
hematologic malignancies, [12-15] breast cancer [16-18]
and colon cancer [19]. Barretina and colleagues have
recently reported aUPD in a limited number of STS
samples [11]. The purpose of this study was to determine
the frequency, distribution of aUPD in 9 subtypes of STS
and identify recurrent aUPD regions specific for each
subtype in a large sample set of STS.
Methods
We retrieved raw data (Affymetrix GeneChip Human
DNA-oligonucleotide SNP array CEL files) from the
Gene Expression Omnibus (GEO) database (www.ncbi.
nlm.nih.gov/geo) for a total of 319 soft tissue sarcoma
(STS) tumor samples from 5 GEO series with the following
accession numbers: GSE8046 (20 samples), [20] GSE15696
(10 samples), GSE20709 (25 samples), [21] GSE21124
(207 tumor samples), [11] and GSE24715 (57 samples)
(Additional file 1: Table S1) [22,23]. We included 315
STS tumor samples that passed quality control (QC) to
determine distribution of genome-wide aUPD pattern,
and excluded 4 samples due to fail the quality control.
The 315 samples consisted of the following subtypes:
alveolar RMS (57), EWS (10), GIST (45), leiomyosarcoma
(27), liposarcoma (115 samples), of which 24 were
pleomorphic liposarcoma, 21 MRC liposarcoma, and
50 were dedifferentiated liposarcoma, or liposarcoma
without subclassified (20 samples), myxofibrosarcoma
(38), and synovial sarcoma (23).
After quality control of the retrieved raw data (CEL files),
we processed the CEL (intensity) files to generate CHP files
by using GeneChip Genotyping Analysis (GTYPE, version
4.1) and Genotyping Console (GTC, version 3.0) software
(Affymetrix, Santa Clara, CA). QC metrics was calculated
as default in GTC. Then, microarray data were analyzed for
determination of allele-specific copy numbers using CNAG
(Copy number analysis for GeneChips) (version 3.4)
software (http://genome.umin.jp) by using a Hidden
Markov Model to predict the presence of aUPD regionsas previously described [24]. Data from each of the array
platforms were independently analyzed by using non
self-controls with automatically selected sex-matched
reference samples from HapMap data and from previously
published, publicly available datasets; GSE14860 [25],
GSE10922 [26], GSE11417 [27], GSE10092 [28], and
GSE15097 [29]. Only GSE21124 data set was analyzed by
matching normal samples. In the aUPD analyses both the
genotype information and the intensity were used. Then all
the data from each array were used to generate aUPD
profiles for each tumor. The total aUPD was calculated by
counting the all aUPD regions. The segmental aUPD was
calculated by counting the aUPD at telomeric and
centromeric regions, and whole chromosomal aUPD was
considered if aUPD occurs in entire chromosome. If
aUPD occurs with one mitotic recombination defined as
telomeric, and if aUPD occurs via two or more mitotic
recombination defined as centromeric. The NCBI Build
36/hg18 (http://genome.ucsc.edu) was used for identifying
gene localization and function. Previously, aUPD was
detected in limited number of STS by using GISTIC
analysis, which is designed to identify copy number
alterations, but not aUPD [11].
Statistical analyses
We performed non-parametric Kruskal-Wallis test to
identify difference of frequency of aUPD regions between
translocation and non-translocation groups of STS and
aUPD regions between segmental and whole chromo-
some, telomeric and centromeric. Frequency of aUPD
describes the number of aUPD per sample. Percentage of
aUPD in each of groups or subtypes was calculated by the
AB
Figure 2 (See legend on next page.)
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Figure 2 Distribution of aUPD in (A) non-translocation and (B) translocation driven soft tissue sarcomas. (A) aUPD regions in non-
translocation driven soft tissue sarcomas; GIST, leiomyosarcoma, myxofibrosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma.
(B) aUPD regions in translocation driven soft tissue sarcomas; myxoid/round cell liposarcoma, synovial sarcoma, Ewing sarcoma, and alveolar
rhabdomyosarcoma. Each red line represents region of aUPD for each soft tissue sarcoma sample. Gene name in red represents most mutated
genes and green represents imprinted genes that previously reported, which are mapped in the aUPD regions.
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p value < 0.05 was considered to be statistically significant.
Statistical analysis was performed using R software version
2.15.0 (http://www.r-project.org/).Results and discussion
Distribution of aUPD patterns in STS
We integrated genomic data from 5 different studies to
allow us to interrogate a large number of samples encom-
passing different types of STS. As indicated in Additional
file 2: Figure S1, aUPD is found across all chromosomes in
STS. We identified aUPD in 47.9% (151/315) of tumor
samples with a range between 0 and 37 regions (mean 2.3,
median 0) with a total of 724 aUPD regions. Segmental
aUPD (630/724; mean 2, median 0) was more frequent
(P < 2.3E-16) than whole-chromosome aUPD (94/724;
mean 0.3, median 0) (Figure 1), suggesting that mitotic re-
combination is a more common mechanism of aUPD gen-
eration in STS than is the loss of one chromosome and
duplication of the remaining chromosome. In addition, we
found that centromeric aUPD (441/724; mean 1.4, median
0) was significantly more common (P < 0.0002) than telo-
meric aUPD (189/724; mean 0.6, median 0) (Figure 1).
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Figure 3 Frequency of total aUPD in (A) each subtype of soft tissue s
myxofibrosarcoma and synovial sarcoma, and (B) each subgroup of li
liposarcoma and myxoid/round cell liposarcoma.indicating that multiple mitotic recombination events
occur frequently in soft tissue sarcoma tumorigenesis.
Strikingly, the patterns of aUPD varied markedly
across STS subtypes (Figure 2A and 2B). Moreover, the
proportion of patients with aUPD were found to vary in
each subtype; 73% (27/37) in myxofibrosarcoma, 62.2%
(28/45) in GIST, 61.4% (35/57) in alveolar rhabdomyo-
sarcoma, 51.9% (14/27) in leiomyosarcoma, 50% (5/10)
in EWS, 35.7% (41/115) in liposarcoma, and no aUPD in
synovial sarcoma (0/23) (Additional file 3: Figure S2A),
and the frequencies which are the counts of aUPD in
each tumor sample are significantly different among
these subtypes (P<2.61E-08, Figure 3A). The proportions
of patients with aUPD are also different among the three
subgroups of liposarcoma: 70.8% (17/24) in pleomorphic
liposarcoma, 24.0% (12/50) dedifferentiated liposarcoma,
and 14.3% (3/21) MRC liposarcoma (Additional file 3:
Figure S2B). The frequencies of aUPD of these three sub-
groups are significantly different (P<9.43E-06, Figure 3B).
Total, centromeric and segmental aUPD were signifi-
cantly more frequent in non-recurrent translocation STS
than recurrent translocation driven STS (P < 3.71E-04,
P < 6.64E-06, P < 1.57E-04, respectively) (Figure 4). We
also identified statistically significant differences in total,




























arcomas; aRMS, EWS, GIST, leiomyosarcoma, liposarcoma,
posarcoma; dedifferentiated liposarcoma, pleomorphic
Figure 4 The comparison of frequency of total, telomeric,
centromic, segmental and whole chromosome aUPD in non-
translocation and translocation driven soft tissue sarcomas.
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to MRC (P < 9.26E-05, P < 6.23E-04, P < 2.12E-04,
respectively), and also comparing both pleomorphic
liposarcoma and dedifferentiated liposarcoma to MRC
(P < 0.02, P < 0.03, P < 0.03). However, no statistically sig-
nificant difference was observed between dedifferentiated
liposarcoma and MRC (P < 0.28, P < 0.26, P < 0.35). The
frequencies of total, telomeric, centromeric, segmental and
whole-chromosome aUPD for each subtype of STS are
summarized in Additional file 4: Figure S3 A-E.
Recurrent aUPD regions
We then assessed the frequency of specific aUPD regions
across different STS subtypes (Figure 2A and 2B). Overall,
the frequency of aUPD across all STS was highest at
chromosome 11p (11.7%) and lowest at 19q (1.1%). Specific
recurrent aUPD regions were found in non-recurrent
translocation driven STS; GIST (Figure 2A), leiomyosar-
coma (Figure 2A), myxofibrosarcoma (Figure 2A), and
pleomorphic liposarcoma (Figure 2A), but not in recur-
rent translocation driven sarcomas; MRC (Figure 2B),
synovial sarcoma (Figure 2B), and EWS (Figure 2B), with
the exception of dedifferentiated liposarcoma (Figure 2A)
and alveolar RMS (Figure 2B).
In GIST, the most frequent aUPD region at chromosome
1p36.11-p35.3 (15.2%) harbors candidate cancer genes
including FGR, RCC1, and TAF12, with less frequent aber-
rations at chromosome 14q11.2-q21.3 (11.1%), at 4q (8.9%)
where KIT and PDGFRA are located, and at chromosome22q11.22-q12.1 (6.7%) (SMARCB1, GSTT1, GSTT2 and
MYO18B) (Figure 2A, Additional file 5: Table S2). Muta-
tions of KIT (75%) and PDGFRA (28%), [21,30,31] and dele-
tions at chromosome 14q (68–70%), 1p (53–56%), and 22q
(40%) are common in GIST [11,21,32]. Genes at chromo-
some 1p (KIF1B, UBE4B, PRDM2 and TP73), and at
chromosome 14q (RTN1, DAAM1 and DACT1) reported
to be under-expressed in GIST samples, are found in
regions of aUPD [21]. Gunawan et al. reported three cyto-
genetic pathways proposed to lead to the initiation and pro-
gression of GIST; one initiated with deletion at 14q,
another initiated with deletion at 1p, and the last one
initiated with deletion at 22q [32]. GISTs with deletion at
chromosome 14q were associated with better disease free
survival (DFS) (P < 0.005), whereas tumors with deletion
at chromosome 1p (P < 0.00007) and 22q (P < 0.004)
were associated with poorer DFS [32]. Taken together,
our data indicates that not just gain-of-function mutations
like KIT and PDGFRA but also loss-of-function mutations
and reduction to homozygosity through aUPD at chromo-
somes 1p, 14q and 22q may contribute to pathophysiology
of GIST.
In leiomyosarcoma, in contrast, the most frequent
aUPD region was at chromosome 17p13.3-p13.1 (TP53)
(25.9%) (Figure 2A, Additional file 5: Table S2), whereas
in myxofibrosarcoma the most frequent aUPD was at
chromosome 1p35.1-p34.2 (EIF2C4 and EIF2C3) (26.3%)
(Figure 2A, Additional file 5: Table S2). Copy number
analysis studies have shown that deletion at chromosome
17p is common in leiomyosarcoma tumor samples, [33]
indicating that the 17p region may harbor tumor
suppressor genes that may be homozygously mutated
or methylated following aUPD.
In pleomorphic liposarcoma, another non-translocation-
related sarcoma, we found aUPD region at 13q (TNFSF11
and RB1) with the most frequent aUPD at chromosome
13q13.2-q13.3 (SMAD9) (Figure 2A, Additional file 1:
Table S1). Previously deletion [10] and aUPD [11] in the
RB1 region at chromosome 13q14.2 were reported in
pleomorphic liposarcoma. Thus, aUPD at 13q13.2-q13.3
and 13q14.11-q14.2 regions may render cells homozygous
of novel genes for existing abnormalities.
In alveolar RMS, the most frequent aUPD region was at
chromosome 11p (29.8%), with the minimal recurrent re-
gion at 11p15.4. Several potential cancer genes map to this
region: TAF10, ILK, and EIF3F (Figure 2B, Additional file 5:
Table S2). aRMS is characterized by loss of imprinting in
IGF2 and H19 [34-36]. Interestingly IGF2 is expressed from
the paternal allele, which may lead to increased expression
of IGF2 while H19 is maternal expressed, and may lead to
suppressed expression of H19 [37]. Thus aUPD in these
regions could result in decreased or increased expression
of candidate cancer genes depending on which parental al-
lele is duplicated.
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regions
Next, we identified aUPD regions with homozygous dele-
tion or focal amplification. aUPD regions with homozygous
deletion that could potentially harbor tumor suppressor
genes are summarized in Additional file 6: Table S3. We
found a focal amplification region at chromosome 11p15.3-
p15.2 (RASSF10, RRAS2, and COPB1) in one tumor sample
of aRMS, where the other aRMS samples harbor aUPD in
the same region (Additional file 6: Table S3). The amplifica-
tion at 11p15.3-p15.2 may increase the level of a gain-of-
function allele in this region.Conclusion
In conclusion, to our knowledge, our study encompasses
the largest sample set available for the analysis of aUPD in
soft tissue sarcoma subtypes. Our results yield a detailed
map of aUPD across 9 diverse sarcoma subtypes. The
frequency and distribution of aUPD is significantly higher
in fusion-negative STS than translocation driven STS
suggesting an alternative mechanism underlying tumor
development. This study provides evidence for a basis for
mutation screening with next-generation sequencing to
identify potential mechanistic mediators and therapeutic
targets for each subtype of STS and particularly for recur-
rent regions specifically associated with translocation nega-
tive STS.Additional files
Additional file 1: Table S1. SNP microarray data summary.
Additional file 2: Figure S1. Distribution of aUPD regions in all soft
tissue sarcoma samples. Each brown line represents aUPD region in each
sample.
Additional file 3: Figure S2. The percentage of aUPD in (A) each
subtype of STS and (B) each subgroup of liposarcoma.
Additional file 4: Figure S3. The frequency of aUPD in translocation
and non-translocation driven soft tissue sarcomas. The frequency of (A)
total aUPD, (B) telomeric aUPD, (C) centromeric aUPD, (D) segmental
aUPD, (E) whole chromosome aUPD in non-translocation and
translocation driven tumors.
Additional file 5: Table S2. Properties of recurrent aUPD regions in
tumor samples of aRMS, GIST, leiomyosarcoma, myxofibrosarcoma, and
pleomorphic liposarcoma tumor samples
Additional file 6: Table S3. aUPD regions with homozygous deletions
and focal amplifications in tumor samples of soft tissue sarcoma
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